SS-31 (Elamipretide) Research & Studies
We track 20 published, PubMed-indexed studies for SS-31 (Elamipretide), spanning 2020 to 2026. The research below includes 13 reviews, 7 clinical trials.
These summaries are for educational purposes. Research findings, particularly from preclinical studies, may not translate to human outcomes. Always consult a qualified healthcare provider before making decisions based on this information.
13
Reviews
7
Clinical Trials
Elamipretide: First Approval.
ReviewShirley M|Drugs|2026
Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential.
ReviewTung C, Varzideh F, et al.|Int J Mol Sci|2025
Contemporary insights into elamipretide's mitochondrial mechanism of action and therapeutic effects.
ReviewSabbah HN, Alder NN, et al.|Biomed Pharmacother|2025
Elamipretide in the Management of Barth Syndrome: Current Evidence and a Case Report.
ReviewJacob N, Schecter D, et al.|Mol Genet Metab|2025
Beyond the injection: delivery systems reshaping retinal disease management.
ReviewRowe LW, Akotoye C, et al.|Expert Opin Pharmacother|2025
Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.
Clinical TrialThompson WR, Manuel R, et al.|Genet Med|2024
Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial.
Clinical TrialKaraa A, Bertini E, et al.|Orphanet J Rare Dis|2024
Elamipretide Topical Ophthalmic Solution for the Treatment of Subjects with Leber Hereditary Optic Neuropathy: A Randomized Trial.
Clinical TrialKaranjia R, Sadun AA|Ophthalmology|2024
Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.
Clinical TrialKaraa A, Bertini E, et al.|Neurology|2023
Identifying responders to elamipretide in Barth syndrome: Hierarchical clustering for time series data.
Clinical TrialVan den Eynde J, Chinni B, et al.|Orphanet J Rare Dis|2023
Temporal evolution of the heart failure phenotype in Barth syndrome and treatment with elamipretide.
ReviewSabbah HN, Taylor C, Vernon HJ|Future Cardiol|2023
Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome.
Clinical TrialHornby B, Thompson WR, et al.|Orphanet J Rare Dis|2022
Elamipretide for Barth syndrome cardiomyopathy: gradual rebuilding of a failed power grid.
ReviewSabbah HN|Heart Fail Rev|2022
Targeting mitochondrial dysfunction with elamipretide.
ReviewObi C, Smith AT, et al.|Heart Fail Rev|2022
SS-31, a Mitochondria-Targeting Peptide, Ameliorates Kidney Disease.
ReviewZhu Y, Luo M, et al.|Oxid Med Cell Longev|2022
Neuroprotective Effects of a Small Mitochondrially-Targeted Tetrapeptide Elamipretide in Neurodegeneration.
ReviewNhu NT, Xiao SY, et al.|Front Integr Neurosci|2021
Barth syndrome cardiomyopathy: targeting the mitochondria with elamipretide.
ReviewSabbah HN|Heart Fail Rev|2021
Potential Therapeutic Candidates for Age-Related Macular Degeneration (AMD).
ReviewNashine S|Cells|2021
A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy.
Clinical TrialKaraa A, Haas R, et al.|J Cachexia Sarcopenia Muscle|2020
Mitochondrial targeted therapy with elamipretide (MTP-131) as an adjunct to tumor necrosis factor inhibition for traumatic optic neuropathy in the acute setting.
ReviewTse BC, Dvoriantchikova G, et al.|Exp Eye Res|2020